Metselaar H J, Ploeg R J, Van Loon A M, Weiland H T, Rothbarth P H, Paul L C, Brand A, Schaafsma R, Hendriks G F, Jeekel J
Department of General Surgery, University Hospital Rotterdam-Dijkzigt, The Netherlands.
Scand J Infect Dis. 1988;20(2):135-9. doi: 10.3109/00365548809032429.
The influence of the cytomegalovirus (CMV) serostatus of blood and kidney donors on patient and graft survival was studied prospectively in 73 cadaveric renal graft recipients. Six out of 12 (50%) CMV seronegative recipients receiving a kidney from a CMV seropositive donor developed CMV disease, in contrast to none of 7 CMV seronegative donor/recipient combinations. Transmission of CMV with blood products to seronegative recipients was not observed in this study. A poor graft survival of 41% 3 years after transplantation was found in CMV seronegative recipients with CMV seropositive allograft donors, compared with an actuarial 3 year graft survival of 72% in the 7 CMV seronegative donor/recipient combinations. Six patients with graft failure had a CMV infection. This study, in accordance with other studies, suggests that selection of CMV seronegative renal allograft donors for CMV seronegative recipients will improve graft survival.
前瞻性研究了73例尸体肾移植受者中，血液和肾脏供者的巨细胞病毒（CMV）血清学状态对患者和移植物存活的影响。12例接受CMV血清阳性供者肾脏的CMV血清阴性受者中有6例（50%）发生了CMV疾病，相比之下，7例CMV血清阴性供者/受者组合中无一例发生。本研究未观察到血液制品将CMV传播给血清阴性受者的情况。CMV血清阴性受者接受CMV血清阳性同种异体移植供者的肾脏后，移植3年后移植物存活率较差，为41%，而7例CMV血清阴性供者/受者组合的3年移植物预期存活率为72%。6例移植失败的患者发生了CMV感染。与其他研究一致，本研究表明，为CMV血清阴性受者选择CMV血清阴性肾移植供者将提高移植物存活率。
